share_log

22nd Century Group to Announce Second Quarter 2024 Results on August 13, 2024

22nd Century Group to Announce Second Quarter 2024 Results on August 13, 2024

22世纪集团将于2024年8月13日宣布2024年第二季度业绩。
newsfile ·  08/06 08:00

Mocksville, North Carolina--(Newsfile Corp. - August 6, 2024) - 22nd Century Group, Inc. (NASDAQ: XXII), a tobacco products company focused on nicotine harm reduction and contract manufacturing, will host a webcast on Tuesday, August 13, 2024, at 8:00 AM ET to discuss its 2024 second quarter results, which are to be reported in a press release at 6:00 AM ET the same day.

北卡罗来纳州莫克斯维尔--(新闻稿公司 - 2024年8月6日)-- 22世纪集团股份有限公司 (NASDAQ: XXII),一家专注于尼古丁伤害缓解和合同制造的烟草制品公司,将于2024年8月13日星期二上午8:00 ET举行网络研讨会,讨论其2024年第二季度业绩,这些业绩将于当天早上6:00 ET通过新闻稿公布。

During the webcast, Larry Firestone, chairman and chief executive officer, and Dan Otto, chief financial officer, will review financial results and discuss progress made in the recent months.

在网络研讨会期间,董事长兼首席执行官拉里·法伊斯通和首席财务官丹·奥托将回顾财务业绩并讨论近几个月的进展情况。

The live and archived webcast will be accessible on the Events web page in the Company's Investor Relations section of the website, at . Please access the website at least 15 minutes prior to the start of the webcast to register and, if necessary, download and install any required software.

现场和归档的网络研讨会可以通过公司网站投资者关系部分的“事件”网页进行访问。请在网络研讨会开始前至少15分钟访问网站进行注册,并在必要时下载和安装所需的软件。

About 22nd Century Group, Inc.

关于22世纪集团公司

22nd Century Group, Inc. (NASDAQ: XXII) is an agricultural biotechnology company focused on tobacco harm reduction by offering tobacco products with 95% less nicotine, designed to improve health and wellness by helping smokers smoke less. Backed by comprehensive and extensively patented technologies that regulate nicotine biosynthesis activities in the tobacco plant, the Company has pioneered the development of high-yield, proprietary reduced nicotine content (RNC) tobacco plants and clinically validated RNC cigarette products. The Company received the first and only FDA Modified Risk Tobacco Product (MRTP) authorization for a combustible cigarette in December 2021. The Company is a subsequent participating manufacturer under the Master Settlement Agreement ("MSA") and vertically integrated for the production of both its own products and contract manufacturing operations ("CMO"), which consist primarily of branded filtered cigars and conventional cigarettes.

22世纪集团股份有限公司 (NASDAQ: XXII) 是一家农业生物科技公司,专注于通过提供含有95%较少尼古丁的烟草产品以减少烟草危害,并旨在通过帮助吸烟者减少吸烟来改善健康和健康状况。该公司通过对烟草植物中尼古丁生物合成活动进行全面和广泛的专利技术调控,开创了高产量的专有减少尼古丁含量 (RNC) 烟草植物和经过临床验证的 RNC 烟卷产品的研发先河。该公司于2021年12月获得了第一个和唯一授予可燃烟卷的 FDA 修改危险烟草产品 (MRTP) 许可。该公司是大众和康卡斯特诉讼达成的大众和康卡斯特协议的后续参与制造商,与自己的产品和合同制造业务 ("CMO") 垂直整合,其主要由品牌过滤雪茄和传统香烟组成。

Learn more at xxiicentury.com, on Twitter, on LinkedIn, and on YouTube.

欲了解更多,请访问 xxiicentury.com,在Twitter、领英和YouTube上了解我们公司的最新动态。

Learn more about VLN at tryvln.com.

了解有关VLN的更多信息,请访问 tryvln.com。

Cautionary Note Regarding Forward-Looking Statements

关于前瞻性声明的谨慎说明

Except for historical information, all of the statements, expectations, and assumptions contained in this press release are forward-looking statements, including but not limited to our full year business outlook. Forward-Looking statements typically contain terms such as "anticipate," "believe," "consider," "continue," "could," "estimate," "expect," "explore," "foresee," "goal," "guidance," "intend," "likely," "may," "plan," "potential," "predict," "preliminary," "probable," "project," "promising," "seek," "should," "will," "would," and similar expressions. Forward-Looking statements include, but are not limited to, statements regarding (i) our strategic alternatives and cost reduction initiatives, (ii) our expectations regarding regulatory enforcement, including our ability to receive an exemption from new regulations, (iii) our financial and operating performance and (iv) our expectations for our business interruption insurance claim. Actual results might differ materially from those explicit or implicit in forward-looking statements. Important factors that could cause actual results to differ materially are set forth in "Risk Factors" in the Company's Annual Report on Form 10-K filed on March 28, 2024 and Quarterly Report on Form 10-Q filed on May 15, 2024. All information provided in this release is as of the date hereof, and the Company assumes no obligation to and does not intend to update these forward-looking statements, except as required by law.

除了历史信息外,本新闻稿中包含的所有声明、期望和假设都是前瞻性声明,包括但不限于我们全年业务展望。前瞻性声明通常包含“预计”、“相信”、“考虑”、“继续”、“可能”、“估计”、“期望”、“探索”、“预见”、“目标”、“指导”、“打算”、“可能”、“计划”、“潜力”、“预测”、“初步”、“可能的”、“项目”、“有前途的”、“寻求”、“应该”、“将”、“愿意”等类似表达。前瞻性声明包括但不限于有关 (i) 我们的战略选择和成本削减措施, (ii) 我们对监管执法的预期,包括我们获得豁免新规定的能力, (iii) 我们的财务和营运业绩以及 (iv) 我们对商业中断保险索赔的预期。实际结果可能会因前瞻性声明所述的明示或暗示的因素而有所不同。可能导致实际结果不同的重要因素在2024年3月28日提交的公司年报10-k中的"风险因素"中说明,以及2024年5月15日提交的季度报告10-Q中说明。本新闻稿中提供的所有信息都是截至此时此刻的,公司对这些前瞻性声明不承担更新的义务,除法律另有要求外。

Investor Relations & Media Contact
Matt Kreps
Investor Relations
22nd Century Group
mkreps@xxiicentury.com
214-597-8200

投资者关系与媒体联系
Matt Kreps
投资者关系
22世纪集团
mkreps@xxiicentury.com
214-597-8200

声明:本内容仅用作提供资讯及教育之目的,不构成对任何特定投资或投资策略的推荐或认可。 更多信息
    抢沙发